- Palvella Therapeutics Showcases Progress on QTORIN Rapamycin Gel for Rare Genetic Disorder MyChesCo
- Daily Derm Times: April 11, 2025 Dermatology Times
- Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% GlobeNewswire
- Chardan Capital Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation Nasdaq
- Chardan Initiates Palvella Therapeutics at Buy With $50 Price Target MarketScreener
